These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 25701378)
1. Celecoxib sensitizes gastric cancer to rapamycin via inhibition of the Cbl-b-regulated PI3K/Akt pathway. Cao Y; Qu J; Li C; Yang D; Hou K; Zheng H; Liu Y; Qu X Tumour Biol; 2015 Jul; 36(7):5607-15. PubMed ID: 25701378 [TBL] [Abstract][Full Text] [Related]
2. Reversal of P-glycoprotein-mediated multi-drug resistance by the E3 ubiquitin ligase Cbl-b in human gastric adenocarcinoma cells. Zhang Y; Qu X; Hu X; Yang X; Hou K; Teng Y; Zhang J; Sada K; Liu Y J Pathol; 2009 Jun; 218(2):248-55. PubMed ID: 19274672 [TBL] [Abstract][Full Text] [Related]
3. PI3K/Akt is involved in bufalin-induced apoptosis in gastric cancer cells. Li D; Qu X; Hou K; Zhang Y; Dong Q; Teng Y; Zhang J; Liu Y Anticancer Drugs; 2009 Jan; 20(1):59-64. PubMed ID: 19343001 [TBL] [Abstract][Full Text] [Related]
4. Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells. Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Pan SY; Chen XW; Zhou SF Drug Des Devel Ther; 2015; 9():1293-318. PubMed ID: 25767376 [TBL] [Abstract][Full Text] [Related]
5. Ubiquitin ligase Cbl-b represses IGF-I-induced epithelial mesenchymal transition via ZEB2 and microRNA-200c regulation in gastric cancer cells. Li H; Xu L; Li C; Zhao L; Ma Y; Zheng H; Li Z; Zhang Y; Wang R; Liu Y; Qu X Mol Cancer; 2014 Jun; 13():136. PubMed ID: 24885194 [TBL] [Abstract][Full Text] [Related]
6. Casitas B-lineage lymphoma mutants activate AKT to induce transformation in cooperation with class III receptor tyrosine kinases. Polzer H; Janke H; Schmid D; Hiddemann W; Spiekermann K Exp Hematol; 2013 Mar; 41(3):271-80.e4. PubMed ID: 23127761 [TBL] [Abstract][Full Text] [Related]
7. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Sun SY; Rosenberg LM; Wang X; Zhou Z; Yue P; Fu H; Khuri FR Cancer Res; 2005 Aug; 65(16):7052-8. PubMed ID: 16103051 [TBL] [Abstract][Full Text] [Related]
8. Arsenic trioxide induces apoptosis and G2/M phase arrest by inducing Cbl to inhibit PI3K/Akt signaling and thereby regulate p53 activation. Li Y; Qu X; Qu J; Zhang Y; Liu J; Teng Y; Hu X; Hou K; Liu Y Cancer Lett; 2009 Nov; 284(2):208-15. PubMed ID: 19457607 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321 [TBL] [Abstract][Full Text] [Related]
10. Rapamycin combined with celecoxib enhanced antitumor effects of mono treatment on chronic myelogenous leukemia cells through downregulating mTOR pathway. Li J; Xue L; Hao H; Li R; Luo J Tumour Biol; 2014 Jul; 35(7):6467-74. PubMed ID: 24682932 [TBL] [Abstract][Full Text] [Related]
11. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway. Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907 [TBL] [Abstract][Full Text] [Related]
12. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631 [TBL] [Abstract][Full Text] [Related]
13. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors. Meric-Bernstam F; Akcakanat A; Chen H; Do KA; Sangai T; Adkins F; Gonzalez-Angulo AM; Rashid A; Crosby K; Dong M; Phan AT; Wolff RA; Gupta S; Mills GB; Yao J Clin Cancer Res; 2012 Mar; 18(6):1777-89. PubMed ID: 22422409 [TBL] [Abstract][Full Text] [Related]
14. Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma. Petrich AM; Leshchenko V; Kuo PY; Xia B; Thirukonda VK; Ulahannan N; Gordon S; Fazzari MJ; Ye BH; Sparano JA; Parekh S Clin Cancer Res; 2012 May; 18(9):2534-44. PubMed ID: 22338016 [TBL] [Abstract][Full Text] [Related]
15. PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/ERK-dependent pathways. Fu X; Feng J; Zeng D; Ding Y; Yu C; Yang B Biosci Rep; 2014 Apr; 34(2):. PubMed ID: 27919028 [TBL] [Abstract][Full Text] [Related]
16. A study on the mechanism of rapamycin mediating the sensitivity of pancreatic cancer cells to cisplatin through PI3K/AKT/mTOR signaling pathway. Li B; Yang J; Lu Z; Liu B; Liu F J BUON; 2019; 24(2):739-745. PubMed ID: 31128031 [TBL] [Abstract][Full Text] [Related]
17. Celecoxib regulates apoptosis and autophagy via the PI3K/Akt signaling pathway in SGC-7901 gastric cancer cells. Liu M; Li CM; Chen ZF; Ji R; Guo QH; Li Q; Zhang HL; Zhou YN Int J Mol Med; 2014 Jun; 33(6):1451-8. PubMed ID: 24676394 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of CD133 Overcomes Cisplatin Resistance Through Inhibiting PI3K/AKT/mTOR Signaling Pathway and Autophagy in CD133-Positive Gastric Cancer Cells. Lu R; Zhao G; Yang Y; Jiang Z; Cai J; Hu H Technol Cancer Res Treat; 2019 Jan; 18():1533033819864311. PubMed ID: 31405336 [TBL] [Abstract][Full Text] [Related]
19. Anti-gastric cancer effects of celecoxib, a selective COX-2 inhibitor, through inhibition of Akt signaling. Kim N; Kim CH; Ahn DW; Lee KS; Cho SJ; Park JH; Lee MK; Kim JS; Jung HC; Song IS J Gastroenterol Hepatol; 2009 Mar; 24(3):480-7. PubMed ID: 18823436 [TBL] [Abstract][Full Text] [Related]
20. Cbl-b promotes chemotherapy-induced apoptosis in rat basophilic leukemia cells by suppressing PI3K/Akt activation and enhancing MEK/ERK activation. Qu X; Li Y; Liu J; Xu L; Zhang Y; Hu X; Hou K; Liu Y Mol Cell Biochem; 2010 Jul; 340(1-2):107-14. PubMed ID: 20177738 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]